Wealth Enhancement Advisory Services LLC Sells 13,320 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Wealth Enhancement Advisory Services LLC reduced its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 55.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,910 shares of the company’s stock after selling 13,320 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Recursion Pharmaceuticals were worth $57,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $36,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after buying an additional 2,026 shares during the last quarter. San Luis Wealth Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $54,000. ADG Wealth Management Group LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $57,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 10.0%

Shares of RXRX opened at $5.32 on Monday. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The firm’s 50 day moving average is $5.07 and its 200-day moving average is $5.10. The stock has a market capitalization of $2.31 billion, a PE ratio of -2.99 and a beta of 0.91. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same period in the prior year, the business posted ($0.40) earnings per share. The firm’s revenue for the quarter was up 33.3% compared to the same quarter last year. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.